Dougherty & Co Maintains a 'Buy' on MAKO Surgical (MAKO); Would You Be My Chum?
Tweet Send to a FriendGet Alerts MAKO Hot Sheet
Price: $11.14 -0.62%
Rating Summary:
4 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
4 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade MAKO Now!
Dougherty & Co maintains a 'Buy' on MAKO Surgical (NASDAQ: MAKO) price target of $18.00 (from $35.00).
Analyst, Junaid Husain, said, "...While we're hopeful for a turnaround on the capital side, we recognize that any sales force realignment is not a quick fix. Nevertheless, we do see some things working in MAKO’s favor including solid procedure traction in the existing installed base and encouraging signs that hip procedures are making an impact—new hip product introductions in 3Q:12 could be an important driver of procedure growth and possibly box placements. While we continue to be believers in the RIO and the MAKOplasty solution for knee and hip arthoplasty, we need to see consistent execution. We’re maintaining our rating for now, but recognize that—after two tough quarters in a row—market sentiment views MAKO Surgical as a show-me story in CY12."
FY12 loss lowered from (0.66) to (0.87) and FY13 from (0.24) to (0.55).
Separately, Husain, did mention three wild card opportunities for MAKO including: 1) New products over immediate horizon; 2) multi-system sales; and 3) Does MAKO get acquired - opportunistic companies may be looking.
For an analyst ratings summary and ratings history on MAKO Surgical click here. For more ratings news on MAKO Surgical click here.
Shares of MAKO Surgical closed at $24.61 yesterday, with a 52 week range of $20.90-$45.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Junaid Husain, said, "...While we're hopeful for a turnaround on the capital side, we recognize that any sales force realignment is not a quick fix. Nevertheless, we do see some things working in MAKO’s favor including solid procedure traction in the existing installed base and encouraging signs that hip procedures are making an impact—new hip product introductions in 3Q:12 could be an important driver of procedure growth and possibly box placements. While we continue to be believers in the RIO and the MAKOplasty solution for knee and hip arthoplasty, we need to see consistent execution. We’re maintaining our rating for now, but recognize that—after two tough quarters in a row—market sentiment views MAKO Surgical as a show-me story in CY12."
FY12 loss lowered from (0.66) to (0.87) and FY13 from (0.24) to (0.55).
Separately, Husain, did mention three wild card opportunities for MAKO including: 1) New products over immediate horizon; 2) multi-system sales; and 3) Does MAKO get acquired - opportunistic companies may be looking.
For an analyst ratings summary and ratings history on MAKO Surgical click here. For more ratings news on MAKO Surgical click here.
Shares of MAKO Surgical closed at $24.61 yesterday, with a 52 week range of $20.90-$45.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Topeka Capital Raises Google (GOOG) Target to $999, Co. on 'Forefront of Innovation'
- Deutsche Bank Raises PT on Access Midstream Partners (ACMP) to $57
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
